MIND4 is an inducer of cytoprotective NRF2 (nuclear factor-erythroid 2 p45-derived factor 2) activity. MIND4 induced NRF2 activation responses in neuronal and non-neuronal cells and reduced production of reactive oxygen species and nitrogen intermediates. MIND4 has potential as part of a synergistic therapy for Huntington's Disease. References: Quinti L, Casale M, Moniot S, Pais TF, Van Kanegan MJ, Kaltenbach LS, Pallos J, Lim RG, Naidu SD, Runne H, Meisel L, Rauf NA, Leyfer D, Maxwell MM, Saiah E, Landers JE, Luthi-Carter R, Abagyan R, Dinkova-Kostova AT, Steegborn C, Marsh JL, Lo DC, Thompson LM, Kazantsev AG. SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models. Cell Chem Biol. 2016 Jul 21;23(7):849-61. doi: 10.1016/j.chembiol.2016.05.015. Epub 2016 Jul 14. PubMed PMID: 27427231.

纯度：≥98%

CAS：1639965-26-6